ADVERSE EFFECTS OF ANTIPARKINSONIAN DRUGSPARKES JD.1981; DRUGS (N.Y.); ISSN 0012-6667; USA; DA. 1981; VOL. 21; NO 5; PP. 341-353; BIBL. 2 P.Article

BROMOCRIPTINE IN THE TREATMENT OF PARKINSONISMPARKES JD.1979; DRUGS; CHE; DA. 1979; VOL. 17; NO 5; PP. 365-382; BIBL. 2 P.Article

DISEASES OF THE CENTRAL NERVOUS SYSTEM. RELIEF OF PAIN: HEADACHE, FACIAL NEURALGIA, MIGRAINE, AND PHANTOM LIMB. = MALADIES DU SYSTEME NERVEUX CENTRAL. SOULAGEMENT DE LA DOULEUR: CEPHALEES, NEVRALGIES FACIALES, MIGRAINES ET MEMBRES FANTOMESPARKES JD.1975; BRIT. MED. J.; G.B.; DA. 1975; NO 5988; PP. 90-92Article

MAZINDOL IN THE TREATMENT OF NARCOLEPSYPARKES JD; SCHACHTER M.1979; ACTA NEUROL. SCAND.; DNK; DA. 1979; VOL. 60; NO 4; PP. 250-254; BIBL. 9 REF.Article

GENETIC STUDY OF NARCOLEPTIC SYNDROMEBARAITSER M; PARKES JD.1978; J. MED. GENET.; GBR; DA. 1978; VOL. 15; NO 4; PP. 254-259; BIBL. 14 REF.Article

SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE.MARSDEN CD; PARKES JD.1977; LANCET; G.B.; DA. 1977; NO 8007; PP. 345-349; BIBL. 21 REF.Article

ALPHA AND BETA DOPAMINE RECEPTORS.DEBONO AG; MARSDEN CD; PARKES JD et al.1976; ACTA NEUROL. BELG.; BELG.; DA. 1976; VOL. 76; NO 3-6; PP. 315-317Article

EFFECT OF NEW DOPAMINE-BLOCKING AGENT (OXIPEROMIDE) ON DRUG-INDUCED DYSKINESIAS IN PARKINSON'S DISEASE AND SPONTANEOUS DYSKINESIAS.BEDARD P; PARKES JD; MARSDEN CD et al.1978; BRIT. MED. J.; G.B.; DA. 1978; NO 6118; PP. 954-956; BIBL. 5 REF.Article

SODIUM VALPROATE IN THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIAPRICE PA; PARKES JD; MARSDEN CD et al.1978; J. NEUROL. NEUROSURG. PSYCHIATRY; GBR; DA. 1978; VOL. 41; NO 8; PP. 702-706; BIBL. 17 REF.Article

BROMOCRIPTINE IN PARKINSONISM: LONG-TERM TREATMENT DOSE RESPONSE, AND COMPARISON WITH LEVODOPA.PARKES JD; DEBONO AG; MARSDEN CD et al.1976; J. NEUROL. NEUROSURG. PSYCHIATRY; G.B.; DA. 1976; VOL. 39; NO 11; PP. 1101-1108; BIBL. 16 REF.Article

METOCLOPRAMIDE AND PIMOZIDE IN PARKINSON'S DISEASE AND LEVODOPA-INDUCED DYSKINESIAS = LE METOCLOPRAMIDE ET LE PIMOZIDE DANS LA MALADIE DE PARKINSON ET LES DYSKINESIES INDUITES PAR LA L-DOPATARSY D; PARKES JD; MARSDEN CD et al.1975; J. NEUROL. NEUROSURG. PSYCHIATRY; G.B.; DA. 1975; VOL. 38; NO 4; PP. 331-335; BIBL. 26REF.Article

PROTECTIVE METHOD AGAINST CEREBRAL ISCHAEMIA DURING SURGICAL TREATMENT OF CAROTID ARTERY STENOSIS = METHODE DE PROTECTION CONTRE L'ISCHEMIE CEREBRALE PENDANT LA CURE CHIRURGICALE DES STENOSES CAROTIDIENNESSABRI S; COTTON LT; PARKES JD et al.1971; EUROP. NEUROL.; SWITZ.; DA. 1971; VOL. 6; NO 1; PP. 361-363; BIBL. 4REF.Serial Issue

COMPLICATED RESPONSE FLUCTUATION IN PARKINSON'S DISEASE: REPONSE TO INTRAVENOUS INFUSION OF LEVODOPAQUINN N; MARSDEN CD; PARKES JD et al.1982; LANCET (BR. ED.); ISSN 0140-6736; GBR; DA. 1982; NO 8295; PP. 412-415; BIBL. 16 REF.Article

CLONIDINE IN PARKINSON DISEASETARSY D; PARKES JD; MARSDEN CD et al.1975; ARCH. NEUROL.; U.S.A.; DA. 1975; VOL. 32; NO 2; PP. 134-136; BIBL. 24REF.Article

DEPRENYL IN THE MANAGEMENT OF RESPONSE FLUCTUATIONS IN PATIENTS WITH PARKINSON'S DISEASE ON LEVODOPASCHACHTER M; MARSDEN CD; PARKES JD et al.1980; J. NEUROL. NEUROSURG. PSYCHIATRY; ISSN 0022-3050; GBR; DA. 1980; VOL. 43; NO 11; PP. 1016-1021; BIBL. 30 REF.Article

CORTICAL AND OPTIC ATROPHY FOLLOWING FULMINANT HEPATIC FAILURE.TUBBS H; PARKES JD; MURRAY LYON IM et al.1977; MED. CHIR. DIGEST.; FR.; DA. 1977; VOL. 6; NO 2; PP. 75-77; BIBL. 11 REF.Article

AMPHETAMINES, GROWTH HORMONE AND NARCOLEPSY.PARKES JD; DEBONO AG; JENNER P et al.1977; BRIT. J. CLIN. PHARMACOL.; G.B.; DA. 1977; VOL. 4; NO 3; PP. 343-349; BIBL. 29 REF.Article

COMPARATIVE TRIAL OF BENZHEXOL, AMANTADINE, AND LEVODOPA IN THE TREATMENT OF PARKINSIN'S DISEASE = ESSAI COMPARATIF DU BENZHEXOL, DE L'AMANTADINE ET DE LA L-DOPA DANS LE TRAITEMENT DE LA MALADIE DE PARKINSONPARKES JD; BAXTER RC; MARSDEN CD et al.1974; J. NEUROL. NEUROSURG. PSYCHIATRY; G.B.; DA. 1974; VOL. 37; NO 4; PP. 422-426; BIBL. 15REF.Article

TREATMENT OF PARKINSON'S DISEASE WITH LEVODOPA COMBINED WITH L-ALPHA METHYLDOPAHYDRAZINE, AN INHIBITOR OF EXTRACEREBRAL DOPA DECARBOXYLASE = TRAITEMENT DE LA MALADIE DE PARKINSON AVEC LA LEVODOPA ASSOCIEE A LA L-ALPHA METHYLDOPAHYDRAZINE. UN INHIBITEUR DE LA DOPA DECARBOXYLASE EXTRACEREBRALEMARSDEN CD; BARRY PE; PARKES JD et al.1973; J. NEUROL. NEUROSURG. PSYCHIATRY; G.B.; DA. 1973; VOL. 36; NO 1; PP. 10-14; BIBL. 13REF.Serial Issue

ALCOHOL AND PARKINSON DISEASELANG AE; MARSDSEN CD; OBESO JA et al.1982; ANN. NEUROL.; ISSN 0364-5134; USA; DA. 1982; VOL. 12; NO 3; PP. 254-256; BIBL. 15 REF.Article

LISURIDE IN THE TREATMENT OF PARKINSONISMSCHACHTER M; SHEEHY MP; PARKES JD et al.1980; ACTA NEUROL. SCAND.; ISSN 0001-6314; DNK; DA. 1980; VOL. 62; NO 6; PP. 382-385; BIBL. 5 REF.Article

PLASMA BROMOCRIPTINE LEVELS, CLINICAL AND GROWTH HORMONE RESPONSES IN PARKINSONISMPRICE P; DEBONO A; PARKES JD et al.1978; BRIT. J. CLIN. PHARMACOL.; GBR; DA. 1978; VOL. 6; NO 4; PP. 303-309; BIBL. 14 REF.Article

BROMOCRIPTINE AND DOPAMINE RECEPTOR SIMULATION.DEBONO AG; MARSDEN CD; ASSELMAN P et al.1976; BRIT. J. CLIN. PHARMACOL.; G.B.; DA. 1976; VOL. 3; PP. 977-982; BIBL. 26 REF.Article

BROMOCRIPTINE TREATMENT IN PARKINSON'S DISEASE.PARKES JD; MARSDEN CD; DONALDSON I et al.1976; J. NEUROL. NEUROSURG. PSYCHIATRY; G.B.; DA. 1976; VOL. 39; NO 2; PP. 184-193; BIBL. 14 REF.Article

PLASMA DISAPPEARANCE AND CEREBRAL EFFECTS OF CHLORPROMAZINE IN CIRRHOSIS = DISPARITION DU PLASMA ET EFFETS CEREBRAUX DE LA CHLORPROMAZINE DANS LA CIRRHOSEMAXWELL JD; CARRELLA M; PARKES JD et al.1972; CLIN. SCI.; G.B.; DA. 1972; VOL. 43; NO 2; PP. 143-151; BIBL. 1 P.Serial Issue